VCEL – Vericel Corporation
VCEL
$29.34Name : Vericel Corporation
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,494,333,184.00
EPSttm : 0.32
Vericel Corporation
$29.34
VCEL — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
10.04
Margin Of Safety %
-4
Put/Call OI Ratio
1.97
EPS Next Q Diff
-0.43
EPS Last/This Y
0.08
EPS This/Next Y
0.35
Price
29.36
Target Price
55.43
Analyst Recom
1.25
Performance Q
-21.88
Upside
-63.0%
Beta
1.23
Ticker: VCEL
19 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-02 | VCEL | 35.33 | 0.45 | 999.99 | 677 |
| 2026-03-03 | VCEL | 34.38 | 0.45 | 0.20 | 679 |
| 2026-03-04 | VCEL | 34.94 | 0.46 | 0.00 | 681 |
| 2026-03-05 | VCEL | 34.03 | 0.46 | 0.00 | 681 |
| 2026-03-06 | VCEL | 33.7 | 0.52 | 0.00 | 627 |
| 2026-03-09 | VCEL | 34.11 | 0.52 | 999.99 | 627 |
| 2026-03-10 | VCEL | 33.39 | 0.55 | 1.00 | 641 |
| 2026-03-11 | VCEL | 32.89 | 0.55 | 0.67 | 641 |
| 2026-03-12 | VCEL | 32.12 | 0.56 | 0.00 | 643 |
| 2026-03-13 | VCEL | 32.11 | 0.56 | 0.00 | 643 |
| 2026-03-17 | VCEL | 32.5 | 0.56 | 2.00 | 637 |
| 2026-03-18 | VCEL | 32.58 | 0.53 | 0.00 | 658 |
| 2026-03-19 | VCEL | 32.73 | 0.53 | 0.00 | 659 |
| 2026-03-20 | VCEL | 31.42 | 0.51 | 999.99 | 654 |
| 2026-03-23 | VCEL | 32.44 | 0.51 | 999.99 | 654 |
| 2026-03-24 | VCEL | 33.12 | 1.07 | 0.00 | 413 |
| 2026-03-25 | VCEL | 31.46 | 1.04 | 2.00 | 418 |
| 2026-03-26 | VCEL | 30.82 | 1.97 | 0.20 | 22925 |
| 2026-03-27 | VCEL | 29.33 | 1.97 | 0.00 | 22926 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
19 items
«
‹
Current Page1 of 1
›
»
19 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-02 | VCEL | 35.39 | 0.5 | - | 0.26 |
| 2026-03-03 | VCEL | 34.41 | 33.9 | - | 0.41 |
| 2026-03-04 | VCEL | 34.91 | 33.9 | - | 0.41 |
| 2026-03-05 | VCEL | 34.03 | 33.9 | - | 0.41 |
| 2026-03-06 | VCEL | 33.70 | 33.9 | - | 0.41 |
| 2026-03-09 | VCEL | 34.17 | 33.9 | - | 0.41 |
| 2026-03-10 | VCEL | 33.39 | 33.9 | - | 0.41 |
| 2026-03-11 | VCEL | 32.90 | 33.9 | - | 0.41 |
| 2026-03-12 | VCEL | 32.13 | 33.9 | - | 0.41 |
| 2026-03-13 | VCEL | 32.53 | 33.9 | - | 0.41 |
| 2026-03-17 | VCEL | 32.53 | 33.9 | - | 0.41 |
| 2026-03-18 | VCEL | 32.31 | 33.9 | - | 0.41 |
| 2026-03-19 | VCEL | 32.74 | 33.9 | - | 0.41 |
| 2026-03-20 | VCEL | 31.44 | 33.9 | - | 0.41 |
| 2026-03-23 | VCEL | 32.42 | 33.9 | - | 0.41 |
| 2026-03-24 | VCEL | 33.10 | 33.9 | - | 0.41 |
| 2026-03-25 | VCEL | 31.45 | 33.9 | - | 0.41 |
| 2026-03-26 | VCEL | 30.81 | 33.9 | - | 0.41 |
| 2026-03-27 | VCEL | 29.36 | 33.9 | - | 0.41 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
19 items
«
‹
Current Page1 of 1
›
»
19 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-02 | VCEL | -7.92 | -0.33 | 9.56 |
| 2026-03-03 | VCEL | -7.92 | -0.33 | 9.56 |
| 2026-03-04 | VCEL | -10.95 | -0.33 | 9.56 |
| 2026-03-05 | VCEL | -10.95 | -0.33 | 9.56 |
| 2026-03-06 | VCEL | -10.95 | -0.33 | 9.56 |
| 2026-03-09 | VCEL | -10.95 | -0.33 | 9.56 |
| 2026-03-10 | VCEL | -10.95 | -0.33 | 9.56 |
| 2026-03-11 | VCEL | -10.95 | -0.33 | 9.56 |
| 2026-03-12 | VCEL | -10.95 | -0.33 | 9.56 |
| 2026-03-13 | VCEL | -10.95 | -0.33 | 9.56 |
| 2026-03-17 | VCEL | -10.95 | -0.33 | 9.56 |
| 2026-03-18 | VCEL | -10.95 | -0.33 | 9.56 |
| 2026-03-19 | VCEL | -10.95 | -0.33 | 9.56 |
| 2026-03-20 | VCEL | -10.95 | -0.33 | 9.56 |
| 2026-03-23 | VCEL | -10.95 | -0.32 | 9.56 |
| 2026-03-24 | VCEL | -10.95 | -0.32 | 9.56 |
| 2026-03-25 | VCEL | -12.92 | -0.32 | 10.04 |
| 2026-03-26 | VCEL | -12.92 | -0.32 | 10.04 |
| 2026-03-27 | VCEL | -12.92 | -0.32 | 10.04 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
19 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
0.45
Avg. EPS Est. Current Quarter
-0.15
Avg. EPS Est. Next Quarter
0.02
Insider Transactions
-12.92
Institutional Transactions
-0.32
Beta
1.23
Average Sales Estimate Current Quarter
63
Average Sales Estimate Next Quarter
72
Fair Value
28.1
Quality Score
80
Growth Score
92
Sentiment Score
13
Actual DrawDown %
57.4
Max Drawdown 5-Year %
-74
Target Price
55.43
P/E
95.32
Forward P/E
37.08
PEG
0.62
P/S
5.39
P/B
4.19
P/Free Cash Flow
60.18
EPS
0.31
Average EPS Est. Cur. Y
0.41
EPS Next Y. (Est.)
0.76
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
5.98
Relative Volume
1.31
Return on Equity vs Sector %
-22.7
Return on Equity vs Industry %
-6.4
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.17
EBIT Estimation
◆
VCEL
Healthcare
$29.34
📉
N/A
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
20/20
Pullback
13/25
Volume
3/15
Valuation
15/20
TP/AR
4/10
Options
2/10
RSI
30.3
Range 1M
4.6%
🚀
N/A
Momentum Growth
Ride accelerating trends
WATCH
Momentum
18/25
Growth
23/30
Estimates
10/20
Inst/Vol
2/15
Options
3/10
EPS Yr
35.2%
EPS NY
83%
52W%
1.9%
💎
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+11.9% upside
Quality
8/30
Valuation
8/30
Growth
20/25
Stability
7/10
LT Trend
4/5
Upside
+11.9%
Quality
80
MoS
-4%
Click a card to see score breakdown
Full Analysis →
Sector: Healthcare
Industry: Biotechnology
Employees: 398
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
VCEL
Latest News
—
Caricamento notizie per VCEL…
stock quote shares VCEL – Vericel Corporation Stock Price stock today
news today VCEL – Vericel Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch VCEL – Vericel Corporation yahoo finance google finance
stock history VCEL – Vericel Corporation invest stock market
stock prices VCEL premarket after hours
ticker VCEL fair value insiders trading